2025 India Cancer Vaccine Market Revenue Opportunities Report
Description
The 2025 India Cancer Vaccine Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cancer Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the cancer vaccine market in India include the Serum Institute of India (SII), Sun Pharmaceutical Industries, Emcure Pharmaceuticals, and GlaxoSmithKline (GSK). The Serum Institute of India is the world’s largest vaccine manufacturer by dose volume and has developed Cervavac, India's first approved HPV vaccine targeting cervical cancer, strongly supported by the Indian government to be provided free to young girls. Sun Pharma, India’s largest drug manufacturer, is expanding its oncology portfolio with targeted immunotherapies like cosibelimab, a PD-L1 inhibitor in clinical review, reinforcing its oncology footprint both within India and globally. Emcure Pharmaceuticals focuses on producing affordable chemotherapy drugs and biologics, including partnerships with Roche and Sanofi for prominent cancer biologics, enhancing access to advanced cancer therapies in India.
Global vaccine giants such as GlaxoSmithKline (GSK) and Merck & Co. also play significant roles in India’s cancer vaccine market. GSK holds a substantial share through its extensive vaccine portfolio including HPV vaccines, while Merck, in collaboration with Moderna, is advancing personalized cancer vaccine clinical trials, such as the mRNA-4157 vaccine for high-risk melanoma. These companies combine global innovation with local partnerships, strengthening India’s capacity and access to cutting-edge cancer vaccines while aligning with governmental initiatives to address prevalent cancers like cervical cancer through vaccination programs and oncology drug development.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cancer Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the cancer vaccine market in India include the Serum Institute of India (SII), Sun Pharmaceutical Industries, Emcure Pharmaceuticals, and GlaxoSmithKline (GSK). The Serum Institute of India is the world’s largest vaccine manufacturer by dose volume and has developed Cervavac, India's first approved HPV vaccine targeting cervical cancer, strongly supported by the Indian government to be provided free to young girls. Sun Pharma, India’s largest drug manufacturer, is expanding its oncology portfolio with targeted immunotherapies like cosibelimab, a PD-L1 inhibitor in clinical review, reinforcing its oncology footprint both within India and globally. Emcure Pharmaceuticals focuses on producing affordable chemotherapy drugs and biologics, including partnerships with Roche and Sanofi for prominent cancer biologics, enhancing access to advanced cancer therapies in India.
Global vaccine giants such as GlaxoSmithKline (GSK) and Merck & Co. also play significant roles in India’s cancer vaccine market. GSK holds a substantial share through its extensive vaccine portfolio including HPV vaccines, while Merck, in collaboration with Moderna, is advancing personalized cancer vaccine clinical trials, such as the mRNA-4157 vaccine for high-risk melanoma. These companies combine global innovation with local partnerships, strengthening India’s capacity and access to cutting-edge cancer vaccines while aligning with governmental initiatives to address prevalent cancers like cervical cancer through vaccination programs and oncology drug development.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
